Fluidigm Q3 Revenues Fall 3 Percent, Beat Analysts' Estimate | GenomeWeb

NEW YORK (GenomeWeb) – Fluidigm said after the close of the market on Thursday that its third quarter revenues dropped 3 percent year over year but increased 3 percent on a constant-currency basis.

For the three months ended Sept. 30, the South San Francisco-based genomics tools company reported $28.6 million in total revenues compared to $29.6 million in the year-ago period and ahead of analysts' consensus estimate of $27.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.